
Moderna, Inc.
-7.39 %
-68.36 %
Yet to be announced
Company Overview
Moderna, Inc. is a biotechnology company focused on developing messenger RNA (mRNA) therapeutics and vaccines. The company gained global recognition for developing one of the first COVID-19 vaccines. Beyond COVID-19, Moderna is developing mRNA-based treatments for various diseases including cancer, cardiovascular conditions, and rare genetic disorders.
The company's main revenue streams come from vaccine sales and partnerships with other pharmaceutical companies for research and development. Their business model is based on developing innovative medical solutions using their mRNA technology platform.
Revenue Sources
PassAfter reviewing Moderna's revenue sources, their income primarily comes from vaccine development and sales, particularly their COVID-19 vaccine. Their other revenue streams are derived from research collaborations and grants for developing medical treatments. These activities are considered halal as they contribute to human health and wellbeing.
Reliance on Interest
Reporting Date | Total Revenue | Total Expense | Interest Income | Interest Expense | Interest Income Ratio | Interest Expense Ratio |
---|---|---|---|---|---|---|
Sept. 30, 2024 | $1.86b | $1.93b | - | - | 0.00% | 0.00% |
June 30, 2024 | $241.0m | $1.6b | - | - | 0.00% | 0.00% |
March 31, 2024 | $167.0m | $1.43b | - | - | 0.00% | 0.00% |
Dec. 31, 2023 | $2.81b | $2.81b | - | - | 0.00% | 0.00% |
Based on the financial data provided for the last four quarters, Moderna shows zero interest income and zero interest expense. The company appears to operate without significant reliance on interest-based financing or income.
Operational Ethics
PassAfter reviewing Moderna's operations and partnerships, there is no evidence of significant ongoing associations with entities involved in human rights violations. The company maintains research and development facilities in various countries, but there are no documented substantial ties to the Chinese Communist Party or the state of Israel.
Login to join the discussion